Bamzireotide navoxetan (VMT-alpha-NET)_Dosage, benefits & legal status
Also known as VMT-alpha-NET, VMT-a-NET, [212Pb]VMT-alpha-NET, 212Pb-VMT-alpha-NET, Pb-212 VMT-alpha-NET, bamzireotide, lead (212Pb) bamzireotide navoxetan, 203Pb-VMT-alpha-NET
The same tumor-seeking peptide family as Lutathera, carrying an alpha emitter instead of a beta one.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Bamzireotide navoxetan (VMT-alpha-NET)?
Plain language first. The technical label stays, but it never stands alone.Overview
This is a hospital cancer treatment for neuroendocrine tumors, not anything that can be bought. It belongs to a family already described on three other pages here, and the family idea is the same each time: neuroendocrine tumors carry a lot of one particular receptor, a small peptide latches onto that receptor, and a radioactive atom bolted to the peptide rides along and irradiates the tumor from the inside. What is different here is the atom. The approved drugs use lutetium-177, an emitter of beta particles that travel a couple of millimeters. This one uses lead-212, a source of alpha particles: much heavier, far more destructive, and stopping within a few cell widths. The trade is precision for power. One thing to hold onto when reading the results. Across all 68 people treated, tumors shrank in 37%. In a smaller group selected afterward for having the target on every measured tumor, that figure was 39% and other measures looked better too. Picking the group after seeing the results is a legitimate way to design the next trial and a weak way to measure this one.
Bamzireotide navoxetan is a peptide radioligand therapy aimed at somatostatin receptor 2, the same target as lutetium-177 dotatate, lutetium-177 edotreotide and RYZ101, all covered here. A somatostatin analog peptide carries a chelator holding lead-212, an alpha generator, so it delivers alpha radiation from inside the tumor instead of the beta radiation the approved drugs of this class use. The same molecule labeled with lead-203 is used for SPECT dosimetry. It is in one trial, NCT05636618, in people with unresectable or metastatic somatostatin-receptor-positive tumors who have had no prior peptide receptor radionuclide therapy. It is approved in no country, and the company is targeting an end-of-phase 2 meeting with the FDA in the first quarter of 2027.
What it's used for
Tested in unresectable or metastatic somatostatin receptor 2 positive tumors, including gastroenteropancreatic and bronchial neuroendocrine tumors, paraganglioma, pheochromocytoma and meningioma, in people who have had no prior peptide receptor radionuclide therapy. Approved in no country and available only inside trials.
How does Bamzireotide navoxetan (VMT-alpha-NET) work?
What it does in the body, and where.The mechanism is shared with three other cards here. What is worth understanding on this page is the swap that distinguishes it, and the way the strongest-looking numbers were arrived at.
- 01The peptide is the postcode, not the drugWell-differentiated neuroendocrine tumors carry far more somatostatin receptor 2 on their surface than healthy tissue does. A somatostatin analog peptide binds that receptor, the receptor pulls the peptide inside, and the radioactive atom attached to the peptide comes with it. The peptide contributes almost nothing therapeutically. Perspective has not published the sequence of this one, so the delivery vehicle here is a known target with an unpublished molecule.
- 02Lead-212 is the payload, and the alpha arrives one step laterLead-212 is not itself an alpha emitter. It decays by beta emission to bismuth-212, and the alpha comes from there. The practical consequence is that the chelator has to keep hold of the daughter atom after the first decay, or the remaining radioactivity goes wherever that loose atom travels. Alpha particles deposit far more energy than beta particles and stop within a few cell widths, so they damage the cell that took up the drug and very little beyond it. That is the whole case for the swap: more destructive where it lands, less reach into healthy tissue.
- 03The same peptide, loaded with a visible isotope, measures the doseLead-203 behaves chemically like lead-212 and emits gamma rays suitable for SPECT, so the same molecule can be imaged. The trial runs a dosimetry substudy on that basis, working out how much radiation reaches the tumor and how much reaches organs, using a harmless label on an identical carrier. Measuring the dose a specific person's tumor will absorb before giving the radioactive version is the part of this platform that the older beta drugs do less well.
- 04How the best numbers were produced, and why that mattersThe headline figures come in two versions. Across all 68 people treated, the objective response rate was 37% and progression-free survival at 18 months was 72%. In a subgroup of 57 people with gastroenteropancreatic tumors whose every measured lesion carried the receptor, those figures were 39% and 75%, with a 95% disease control rate. The company describes that second analysis as retrospective and says it supports focusing future work on that population. That is a reasonable way to design the next trial. It is a weak way to measure this one, because a group chosen after the results are visible will tend to look better than the whole.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
All 68 treated patients, the figures without subgroup selection
Investigational- human-earlyObjective response 25 of 68, 37%. Disease control 62 of 68, 91%. Data as of September 10, 2026.
- human-earlyProgression-free survival 85% at 6 months, 74% at 12 months, 72% at 18 months across cohorts 1 to 3.
- human-earlyBy cohort: response 15 of 46, 33%, in cohort 2 and 10 of 20, 50%, in cohort 3. Disease control 89% and 95%.
- No dataMedian follow-up differs sharply by cohort: 128 weeks for cohort 1, 76 weeks for cohort 2, 34 weeks for cohort 3. Cohort 3 looks better on response and has no estimable 18-month survival figure, so the two cohorts are not yet comparable.
The gastroenteropancreatic subgroup, and how it was chosen
Investigational- human-earlyIn a retrospectively identified subgroup of 57 patients with gastroenteropancreatic tumors whose every measured lesion carried the receptor: response 22 of 57, 39%; disease control 54 of 57, 95%; progression-free survival 91% at 6 months, 78% at 12 months, 75% at 18 months.
- human-earlyWithin that subgroup, cohort 3 reached 8 of 17, 47%, for response and 17 of 17, 100%, for disease control, on 17 patients.
- No dataThe company states this analysis is retrospective and presents it as the rationale for concentrating future work on that population. Every reported measure is better in the selected group than in the whole. That is what selection after the fact tends to produce.
- No dataOf 8 initial responses in cohort 3, 5 were confirmed and 3 remained pending confirmation at the data cut, so the response rates quoted for that cohort include unconfirmed responses.
Safety across 68 patients
Investigational- human-earlyNo dose-limiting toxicities, no treatment-related discontinuations and no serious adverse events related to study medication in the reporting window.
- human-earlyGrade 3 adverse events in 20 of 68 patients, 29%, with no grade 4 or grade 5 events.
- human-earlyGrade 3 blood-count events in 5 of 68, 7.4%, with no myelodysplastic syndrome reported and no intervention required for low lymphocytes.
- human-earlyGrade 3 kidney events in 2 patients, 3%, both acute kidney injury: one assessed as possibly related and ongoing, one as unlikely related and resolved. This is the only organ where a possibly related severe event has been reported.
How the patient count has grown across readouts
Investigational- human-early42 patients treated at the readout reported in a 2026 endocrine conference abstract, with efficacy assessed in the 9 enrolled for dose-limiting toxicity observation.
- human-early56 patients across cohorts 1 to 3 at a December 10, 2025 data cut, in the AACR 2026 abstract.
- human-early68 patients at the September 10, 2026 data cut reported in November 2026.
- No dataEach release is a different data cut on a growing trial. Numbers quoted from two different releases describe two different populations, so they cannot be set against each other as though the trial had changed.
Regulatory position and what comes next
Investigational- RegulatoryThe company is targeting an end-of-phase 2 meeting with the FDA in the first quarter of 2027, and says it expects agency feedback and the completion of necessary activities to allow a phase 3 to start in 2027.
- RegulatoryThe trial has run since September 27, 2023, lists 300 estimated participants across 20 US sites, and gives an estimated primary completion of November 26, 2029.
- RegulatoryApproved in no country. No orphan designation or marketing application for this generic name was found on the public record checked.
The first error is quoting the subgroup figures as the trial result. The numbers that travel best, 39% response and 95% disease control and 75% progression-free survival at 18 months, belong to 57 patients with gastroenteropancreatic tumors whose every measured lesion carried the receptor, a group the company itself describes as retrospectively identified. Across all 68 patients treated the figures are 37%, 91% and 72%. The second error is reading cohort 3's 50% response rate as better than cohort 2's 33% without the follow-up times: 34 weeks against 76 weeks, with cohort 3's 18-month survival not estimable and three of its responses still unconfirmed. The third is repeating the company's comparison against an approved product's label without saying it is a cross-trial comparison. The release does not name the product, and setting one trial's response rate against another trial's label is not evidence of superiority. The fourth is mixing per-dose and cumulative radioactivity. The cohorts are described as up to 10, 20 and 24 mCi in total, and separately as up to 5 and 7.5 mCi per dose, and for cohort 3 the two descriptions do not reconcile. The fifth is assuming this drug can be compared with the approved lutetium drugs on the same patients: the trial excludes anyone who has had prior radionuclide therapy, so the populations differ by design. One naming note: the generic name is bamzireotide navoxetan, and the company has begun calling the drug bamzireotide for short, so recent coverage uses the short form and the development code VMT-alpha-NET interchangeably.
The published record
Papers about Bamzireotide navoxetan (VMT-alpha-NET)
Searched: bamzireotide navoxetan, bamzireotide, VMT-alpha-NET, VMT-a-NET, 212Pb-VMT-alpha-NET.
Left out: RYZ101 (THE critical rejection. SAME receptor (SSTR2), SAME alpha-therapy concept, SAME octreotate-family targeting idea, but a DIFFERENT isotope (actinium-225, 9.92-day half-life against 10.6 hours) and a DIFFERENT company. Already on this site with its own slug and its own phase 3. These two are the easiest pair on the site to merge, and merging them would attach a phase 3 interim result to a phase 1/2a asset); actinium-225 dotatate (the same compound as RYZ101 under its descriptive name, and its INN is actinium (225Ac) oxodotreotide); lutetium-177 dotatate (THE second critical rejection. The APPROVED beta-emitting drug for the same receptor, already on this site. The company's own November 2026 release sets its figures beside an UNNAMED approved radiotherapy's US package insert showing 13% objective response and about 65% progression-free survival at 18 months. The release does not say which product, so the card must NOT name one, and those two figures must never be attached to this drug); Lutathera (the brand name of that approved drug, and the name most likely to be substituted for the unnamed comparator); lutetium-177 edotreotide (the OTHER beta-emitting SSTR2 radioligand on this site, unapproved after a complete response letter, with its own phase 3 against everolimus. Three SSTR2 radioligands already exist here and this is the fourth); ITM-11 (that drug's development code); octreotide (the non-radioactive somatostatin analog on this site and the parent of the whole targeting family. Every somatostatin keyword search returns it); lanreotide (a second non-radioactive analog here, sold as a depot); pasireotide (a third, multi-receptor rather than SSTR2-selective); DOTATATE (the chelator-peptide name shared by the two lutetium drugs and RYZ101, and NOT this compound's chelator, which the company calls PSC); DOTATOC (the same problem for the edotreotide card); SSTR2 (the receptor class term, returning the entire peptide receptor radionuclide therapy literature); PRRT (the class term for the treatment type. Note the inverse trap: this trial EXCLUDES anyone who has had prior PRRT, so records mentioning PRRT alongside this drug are usually describing who was kept out); lapemelanotide zapixetan (the same company's melanoma program, same isotope and same chelator, different receptor and different disease. Added in the same batch with its own slug); PSV359 (the company's third program, against fibroblast activation protein alpha, on no page here and held back pending a first efficacy readout or an INN); neuroendocrine tumor (far too broad, returning the whole oncology literature for the tumor type).
6 papers tagged human · 5 not reviews or lab · 1 clinical trial publications
Furthest stage reached: Published trials only, 1 clinical trial publication, no phased trial registered
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.
At a glance
Four things to know about Bamzireotide navoxetan (VMT-alpha-NET)
Evidence
Investigational
Category
Sexual and hormonal
Common vial
Varies
Half-life
Lead-212 decays over about 10.6 hours; no human blood half-life published for this drug
How much, and do you cycle it?
The range, and whether you take breaks.Up to 10, 20 or 24 mCi in total by cohort, across up to four doses, every 8 weeks, up to four times. Up to four doses about 8 weeks apart, then stop Trial dose
A finite course rather than ongoing treatment, limited by cumulative radiation dose to kidney and marrow. The 8-week spacing exists to let both recover between doses.
How long does it stay in the body?
The half-life, and where the figure comes from.Lead-212 decays over about 10.6 hours; no human blood half-life published for this drugNo figure
Two separate clocks, often merged. The isotope's physical half-life is about 10.6 hours and that is fixed physics. How long the peptide itself circulates in a person is a different measurement, and the trial lists pharmacokinetics among its objectives without a published figure. The short physical half-life has a practical consequence: the drug has to be made close to where it is given, and the company has built its own generator network for that. For comparison, lutetium-177 decays over 6.647 days, long enough for the approved drugs of this class to be shipped.
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Given in hospital from a prepared product, so there is nothing to mix.
Trial range: 10 up to 24 mCi per course. ClinicalTrials.gov record NCT05636618
Prepared and infused by licensed staff in a nuclear medicine unit, so no vial draw exists and the reconstitution calculator does not apply. The figures above are cumulative totals across a course: the company reports cohort 1 at up to 10 mCi, cohort 2 at up to 20 mCi and cohort 3 at up to 24 mCi, given as up to four doses about 8 weeks apart. Published conference abstracts instead give per-dose levels, reporting the drug as safe up to 5 mCi per dose and the safety committee supporting escalation to 7.5 mCi per dose for cohort 3. Those two sets of numbers do not reconcile arithmetically for cohort 3, and no source checked explains the gap, so both are reported here as published and neither is adjusted to fit the other. A later cohort is described by the company as using front-loaded dosing, a schedule that would change the arithmetic again. The protocol gives protective amino acids alongside each infusion.
How do you store it?
Before mixing, and after.Given in a hospital or trial clinic, so the pharmacy stores it.
Bamzireotide navoxetan (VMT-alpha-NET) goes into a vein and is prepared by hospital, clinic or trial pharmacy staff, following the product label or the trial protocol. Some products like this are ready-made solutions and others are powders mixed just before use, often with hours rather than weeks of shelf life once prepared. It is not a medicine people store at home.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Prior peptide receptor radionuclide therapy, an exclusion criterion in the only trial, so the results describe people who have never had a drug of this class
- Any expectation of access outside a trial, since the drug is approved nowhere and lead-212 decays with a half-life measured in hours, so a vial cannot be shipped or stored
- Comparing the 37% response rate against the figures in an approved drug's label, since the trials enrolled different people against different comparators and neither measures the other
- Reading the gastroenteropancreatic subgroup figures as the trial result, since that group was identified after the data were seen
Stop and get help
- Given in a nuclear medicine unit under specialist supervision, so there is no self-administered dose to stop
- Falling urine output, new swelling or breathlessness between doses, all needing same-day assessment for kidney injury, the one organ where this trial has reported possibly related grade 3 events
- Fever, unusual bruising or bleeding between doses, all needing urgent blood counts for marrow suppression
Common effects
- No per-event breakdown has been published. What the company has released is the grade 3 rate of 29% with no grade 4 or 5 events, plus the organ-specific figures for blood counts and kidneys.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Bamzireotide navoxetan (VMT-alpha-NET) approved?
And where the numbers on this page come from.No. Bamzireotide navoxetan (VMT-alpha-NET) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteInto a vein, in a nuclear medicine unit, about every 8 weeks for up to four doses
- Checked8 November 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesPerspective Therapeutics, NANETS 2026 interim data and analysesClinicalTrials.gov record NCT05636618Cancer Research, AACR 2026 abstract CT088Journal of Clinical Oncology, ASCO Gastrointestinal Cancers Symposium 2025 abstract 668FDA Global Substance Registration System, lead-212 formNCI Thesaurus concept C211711Perspective Therapeutics, ESMO 2026 interim resultsClinicalTrials.gov record NCT05111509, the phase 0 imaging studyPerspective Therapeutics, VMT-alpha-NET program page
What has happened recently
Approved in no country. The only trial is NCT05636618, phase 1/2a, recruiting, 300 estimated participants at 20 US sites, started September 27, 2023, with estimated primary completion November 26, 2029. Prior peptide receptor radionuclide therapy is an exclusion criterion, so the trial enrolls only people who have never had a drug of this class. Interim data were presented at the ESMO congress in October 2026 and at the NANETS symposium announced November 5, 2026. The company says it is targeting an end-of-phase 2 meeting with the FDA in the first quarter of 2027 and expects to be able to start a phase 3 during 2027. No orphan designation for this generic name was found, and the FDA orphan drug database declined to run a query in this session, so that absence is unconfirmed rather than established. The sponsor is Perspective Therapeutics, Inc., Seattle, listed on NYSE American as CATX. A separate phase 0 imaging study of the lead-203 form is registered as NCT05111509, and that one is investigator-led: Yusuf Menda at the University of Iowa is the sponsor and Perspective is listed only as a collaborator.
You can compare this against the whole library, or read how to check a seller.
What else is like Bamzireotide navoxetan (VMT-alpha-NET)?
Others in Sexual and hormonal, side by side.If you're weighing Bamzireotide navoxetan (VMT-alpha-NET), it's worth reading Carbetocin (Pabal, Duratocin), Cetrorelix (Cetrotide), and Degarelix (Firmagon) in the same class.
The same tumor-seeking peptide family as Lutathera, carrying an alpha emitter instead of a beta one.
- Dose
- Up to 10, 20 or 24 mCi in total by cohort, across up to four doses
- How often
- Every 8 weeks, up to four times
A modified oxytocin with a carbon-sulfur ring that keeps the womb contracted for hours after one injection. Matched oxytocin in a 29,645-woman trial.
- Dose
- 100 mcg once, after the baby is delivered (label)
- How often
- Once
A GnRH antagonist used in IVF to stop an egg being released too early.
- Dose
- Set by the label
- How often
- Daily during an IVF cycle
A GnRH antagonist for prostate cancer, and the one with no testosterone flare.
- Dose
- Set by the label
- How often
- Loading dose, then monthly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Perspective Therapeutics, NANETS 2026 interim data and analyses(2026)Dateline November 5, 2026, data as of September 10, 2026. 68 patients received at least one dose across cohorts 1 to 3, at cumulative doses of up to 10, 20 and 24 mCi, up to four doses every eight weeks. Median follow-up 128, 76 and 34 weeks by cohort. All patients: response 25 of 68, 37%; disease control 62 of 68, 91%; progression-free survival 85%, 74% and 72% at 6, 12 and 18 months. Gastroenteropancreatic subgroup with all target lesions receptor-positive, described by the company as retrospective: response 22 of 57, 39%; disease control 54 of 57, 95%; survival 91%, 78% and 75%. Cohort 3 within that subgroup, 8 of 17 responses with 5 confirmed and 3 pending. Safety across all 68: no dose-limiting toxicities, no treatment-related discontinuations, grade 3 events in 20 of 68, 29%, no grade 4 or 5, grade 3 blood-count events 5 of 68, 7.4%, grade 3 kidney events in 2 patients, 3%. Targeting an end-of-phase 2 meeting in the first quarter of 2027. The release sets its figures beside an unnamed approved radiotherapy's US label figures of 13% response and about 65% survival at 18 months, a cross-trial comparison and not a head-to-head trial.
- ClinicalTrials.gov record NCT05636618(2026)Phase 1/2, recruiting, sponsor Perspective Therapeutics, 300 estimated participants at 20 US sites. Actual start September 27, 2023; estimated primary completion November 26, 2029; last update posted October 13, 2026. Interventions are the lead-212 therapeutic by infusion and the lead-203 form as a bolus for SPECT dosimetry. Conditions are unresectable or metastatic neuroendocrine tumors, gastroenteropancreatic and bronchial neuroendocrine tumors, paraganglioma, pheochromocytoma and meningioma. The dose-finding arm gives up to four administrations about eight weeks apart. Patients must be naive to peptide receptor radionuclide therapy, and prior yttrium-90 or lutetium-177 dotatate or dotatoc is an exclusion criterion.
- Cancer Research, AACR 2026 abstract CT088(2026)Volume 86, issue 8 supplement, page CT088, published April 17, 2026, nineteen authors with Thorvardur R. Halfdanarson first. Reports safety and preliminary efficacy from dose-finding cohorts 1, 2 and 3 at a December 10, 2025 data cut, with 56 participants having received at least one dose and promising activity described at the 2.5 and 5 mCi per-dose levels. DOI resolved at Crossref before being recorded here.
- Journal of Clinical Oncology, ASCO Gastrointestinal Cancers Symposium 2025 abstract 668(2025)Volume 43, issue 4 supplement, page 668, published January 27, 2025, nine authors with Richard L. Wahl first. The first-in-human dose-escalation report. States the drug safe up to 185 MBq, 5 mCi, with the safety monitoring committee supporting escalation to cohort 3 at 277.5 MBq, 7.5 mCi. Cohorts 1 and 2 underwent dosimetry with the lead-203 form, therapy was given for four cycles every eight weeks alongside protective amino acids, and primary objectives were safety, tolerability, pharmacokinetics, recommended phase 2 dose and response by RECIST 1.1. DOI resolved at Crossref before being recorded here.
- FDA Global Substance Registration System, lead-212 form(2026)UNII D2A42X3LCS, substance class chemical, formula C72H104N16O20S2 with one lead atom, molecular weight 1789.8182. Two moieties: the ligand C72H104N16O20S2 at 1577.8263 with charge minus two, and the lead-212 ion at 211.9919 with charge plus two. CAS 2941523-47-1, INN 13292, NCI Thesaurus C211711, PubChem 172866335. The only name flagged with name organization INN ends in navoxetan. A non-labeled to labeled relationship links it to the unlabeled peptide, UNII YZ3YX5R472, formula C72H106N16O20S2. No protein, nucleic acid or structurally diverse block exists, so the registry holds no sequence.
- NCI Thesaurus concept C211711(2026)Preferred name Lead Pb 212 Bamzireotide Navoxetan, with the FDA entry for UNII D2A42X3LCS as the source of the synonym. Carries no development code name, so this record does not by itself connect the generic name to VMT-alpha-NET, and it is not independent of the FDA record it cites.
- Perspective Therapeutics, ESMO 2026 interim results(2026)Dateline October 23, 2026. Reports durable disease control in all three cohorts and 72% progression-free survival at 18 months across all patients who received at least one treatment, with response rates of 33% in cohort 2 and 50% in cohort 3, and states the drug remained well-tolerated with no dose-limiting toxicities and no discontinuations due to adverse events. These figures match the all-patients column of the November release, so the two readouts agree on the unselected population.
- ClinicalTrials.gov record NCT05111509, the phase 0 imaging study(2026)A Phase 0 First-in-human Clinical Trial of the lead-203 form for somatostatin receptor imaging of neuroendocrine tumors, registered as early phase 1. Sponsor is Yusuf Menda at the University of Iowa, with Perspective Therapeutics as an industry collaborator rather than the sponsor, so this imaging work is investigator-led and not a company trial. Active and not recruiting, 20 estimated participants, actual start August 22, 2022, estimated primary completion April 30, 2026. The imaging dose is 3 to 5 mCi given into a vein 60 minutes before SPECT and CT scans spread over about three days. Conditions are grade 1 and grade 2 neuroendocrine tumors.
- Perspective Therapeutics, VMT-alpha-NET program page(2026)States that the molecule can be labeled with lead-203 for SPECT imaging and lead-212 for alpha particle therapy, using the company's proprietary chelator. Describes the trial as recruiting across the US in patients naive to peptide receptor radionuclide therapy, and records the December 10, 2025 data cut in 56 patients across three cohorts.
Beyond these, 10 records are indexed. Browse the records